People · Operator
Named in public records as an officer, director or promoter · active 2020–2026 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Lycia Therapeutics, Inc. | — | Biotechnology | Series D+ | $202.0M | $1.2B | 2024 |
| Clear Labs, Inc. | — | Biotechnology | Series C | $135.8M | $218.5M | 2024 |
| Lycia Therapeutics, Inc. | Director | Biotechnology | Series C | $75.0M | $314.3M | 2026 |
| LifeSprout, Inc. | — | Biotechnology | Series B | $23.9M | $841.2M | 2020 |
Ming Fang at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ming Fang on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Clare Ozawa | 2 | 8 |
| William Rieflin | 2 | 4 |
| Laurent Fischer | 2 | 4 |
| TIM ANDERSON | 2 | 3 |
| Aetna Wun Trombley | 2 | 3 |
| Gaurav Garg | 1 | 12 |
| Greg Yap | 1 | 8 |
| Mostafa Ronaghi | 1 | 8 |
| Thomas Woiwode | 1 | 7 |
| Michael Taylor | 1 | 7 |
| Farzad Naimi | 1 | 5 |
| Brian Hogan | 1 | 4 |
| Kazutaka Ohno | 1 | 4 |
| Adam Gridley | 1 | 4 |
| GREGORY SIECZKIEWICZ | 1 | 2 |
| Richard Murdock | 1 | 2 |
| Eric Goorno | 1 | 2 |
| Amrit Nagpal | 1 | 2 |
| Michael Robach | 1 | 1 |
| Mostafa H. Ronaghi | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.